NCT01365637View on ClinicalTrials.gov

The Safety and Tolerability of PF-05089771 Will be Investigated in Healthy Subjects Over a 14 Day Dosing Period.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Pain
Interventions
DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension twice daily

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension either twice or thrice daily

DRUG

PF-05089771

PF-05089771 will be dosed as a suspension either twice or thrice daily

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY